Retatrutide: Potential Availability of New Weight-Loss Medication | Retatrutide News

Retatrutide is a new GLP-1 agonist in Eli Lilly's metabolic pipeline, aimed at weight loss. Details on its public availability are not yet specified.
Market News · November 1, 2026